Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly’s stock dives
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Eli Lilly isn't selling as much Zepbound as expected — and the stock is sinking
Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was anticipating.
Eli Lilly’s stock dives as Mounjaro and Zepbound sales miss, but Citi says buy
Eli Lilly’s stock heads for biggest selloff in more than 4 years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly Stock Tumbles After Disappointing Mounjaro, Zepbound Drug Sales
Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven
Eli Lilly Stock Plummets As Zepbound, Mounjaro Sales Miss Estimates
Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss medicine Zepbound will be virtually bottomless. After the company reported disappointing third-quarter results Wednesday morning,
1h
Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent company ...
4h
on MSN
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
12h
on MSN
Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss
Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...
6h
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
3h
Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St.
The S&P 500 slipped 0.3 percent after drifting between small gains and losses several times, though it's still near its ...
13h
on MSN
Eli Lilly Misses Quarterly Profit Estimates; Shares Tumble
(Reuters) -Eli Lilly missed Wall Street estimates for third-quarter profit on Wednesday, hurt by higher manufacturing costs ...
9h
Eli Lilly: The Stock Might Have Peaked
Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...
6h
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
2d
on MSN
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
4h
on MSN
Nasdaq edges back from its record as chip companies and Eli Lilly slump
U.S. stock indexes edged lower after drops for Eli Lilly and chip companies overshadowed a jump for Google's parent company ...
1d
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Zepbound
Mounjaro
New York Stock Exchange
NASDAQ
United States
Feedback